Repligen Corporation (NASDAQ:RGEN) Receives $166.43 Average Price Target from Analysts

Shares of Repligen Corporation (NASDAQ:RGEN) have been given an average recommendation of “Buy” by the eighteen analysts that are currently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating, twelve have issued a buy rating and three have issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $168.5714.

A number of research analysts have recently weighed in on the stock. Wolfe Research started coverage on shares of Repligen in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 target price for the company. Wells Fargo & Company upped their price objective on Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. Weiss Ratings raised Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, August 13th. Royal Bank Of Canada began coverage on Repligen in a research note on Thursday, May 14th. They issued an “outperform” rating and a $160.00 target price on the stock. Finally, Citigroup raised Repligen to a “buy” rating in a research report on Tuesday, July 7th.

Repligen Stock Performance

Shares of Repligen stock opened at $164.68 on Friday. The business’s fifty day simple moving average is $157.76 and its 200 day simple moving average is $135.08. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. Repligen has a 12 month low of $100.99 and a 12 month high of $188.73. The firm has a market capitalization of $9.29 billion, a P/E ratio of 225.59, a price-to-earnings-growth ratio of 3.01 and a beta of 1.05.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. The company had revenue of $204.13 million for the quarter, compared to analysts’ expectations of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.26 EPS. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, analysts anticipate that Repligen will post 2.06 EPS for the current year.

Insider Transactions at Repligen

In related news, CFO Jason Garland sold 733 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. The trade was a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.60% of the company’s stock.

Hedge Funds Weigh In On Repligen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Measured Wealth Private Client Group LLC bought a new stake in shares of Repligen in the third quarter valued at approximately $29,000. Los Angeles Capital Management LLC bought a new position in Repligen in the 4th quarter worth approximately $36,000. Northwestern Mutual Wealth Management Co. purchased a new position in Repligen in the 2nd quarter valued at approximately $52,000. Farther Finance Advisors LLC grew its stake in Repligen by 61.8% in the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 128 shares in the last quarter. Finally, Itau Unibanco Holding S.A. grew its stake in Repligen by 38.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 104 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to develop and produce biologic drugs. Its products are designed to support key stages of biomanufacturing, including upstream processing, downstream purification, filtration, and process monitoring.

The company’s portfolio includes chromatography products, filtration and single-use systems, process analytics technologies, and recombinant proteins such as Protein A-based products.